Although the history of ADC development ... the cell and the cytotoxic payload is released. This mechanism has already proven effective in several solid tumours and blood cancers.

Typically, PK assays focus on measuring conjugated antibodies, total antibodies, and the released ... ADC drugs. During the preclinical and clinical phases of ADC drug development, these payload ...

In that poster, we used [a] MMAE payload.” At the Piper Sandler event, Ferra declined to answer an analyst’s question about whether the ADC uses site-specific conjugation. The deal clears up ...

Synaffix gives Elevation Oncology global access to its clinical stage, site-specific ADC technology platform, including GlycoConnect® antibody conjugation technology, HydraSpace® ...

a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an exclusive license agreement for SHR-4849, a novel ...

EO-1022 is a differentiated ADC containing seribantumab, an anti-HER3 monoclonal antibody (mAb), and a monomethyl auristatin E (MMAE) payload, with site-specific conjugation to the glycan.

The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms ... This press release shall not constitute an offer ...

SHR-4849 is a novel DLL3-targeting Topo-I-payload antibody drug conjugate or ADC program in Small Cell Lung Cancer or SCLC, and Neuroendocrine Tumors or NETs. SHR-4849 has shown promising ...